Decode the G‑BA

with MBM Future Health

 

Ensure that patients receive the best possible treatment.

Achieve a fair reimbursement for your medicine.

Reach your full potential in the AMNOG procedure.

 Ultimately, rely on my long-standing experience at the G-BA.

 

Identifying the best strategy for a global clinical development of innovative medicines is extremely challenging.

Uncertainty increases when evidence is scarce, as it is often the case in rare diseases and precision medicine. What is the best value proposition for future assessment and reimbursement? Which endpoints will – in the end – be considered patient-relevant? Is the launch in Germany a good option?

Together with you, I identify the best scenario to ensure optimum results for your medicine.

 

 

Launching a product is a critical task.

Procedures at the G-BA are complex. Decision-making authorities are difficult to understand. How to decrypt evidence-based decision making? How to make an informed decision on your individual case with your team?

Get tailored advice on decision-making procedures at the G‑BA for your individual case. 

 

 

 

Ace of spades as symbol for luck with MBM Future Health

Your unique benefits

G-BA Expertise

You benefit from my long-standing experience as G-BA Officer.

Your personal Expert

You receive advice solely from me.

Operating worldwide

You want me in person!

Dr. Meriem Bouslouk-Marx

MEET

Dr. Meriem Bouslouk-Marx

Extensive experience at the G-BA Individual advice for a wide range of therapeutic areas First-hand knowledge of evidence-based decision criteria for reimbursement Specialisation in Orphan Drugs including Cell and Gene Therapy Products Scientific Consultation  Professional Network with Complementary Expertise Medical background including Tropical Medicine Public Health projects International Experience Multilingual (German, French, Arabic, English) Lecturer in Market Access Public Speaker

MORE INFORMATION

in action

Lecturer and Speaker at the Market Access Society (MAS). MORE INFORMATION

Adviser at Project HERCULES, a Duchenne UK Global Collaboration. MORE INFORMATION

Speaker at the Brazilian Health Regulatory Agency Anvisa. GENE AND ADVANCED THERAPIES: Creating Value in the Patient Journey and the Health System. MORE INFORMATION

Adviser with the Alliance for Regenerative Medicine (ARM). Getting Ready: Recommendations for Timely Access to Advanced Therapy Medicinal Products (ATMPs) in Europe. MORE INFORMATION

 

in references

AMED, Japan Agency for Medical Research and Development (2020) Development Trend Survey of Ultra Orphan Drugs. MORE INFORMATION

Schoonveld, E. (2020). The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation (3rd ed.). Routledge. MORE INFORMATION

OECD, Organisation for Economic Co-operation and Development (2018) Pharmaceutical Reimbursement and Pricing in Germany. MORE INFORMATION

Get in Touch